Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 3Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 3Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1

Conditions

Sarcoma 1

Interventions

Doxorubicin 7Radiotherapy 4Radiation 3Magnetic Resonance Spectroscopy 3Ifosfamide 3regorafenib 2Temozolomide 2Surgical Procedures, Operative 2Methotrexate 2Imatinib Mesylate 2Etoposide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2veliparib 1selinexor 1pirarubicin 1pazopanib 1niraparib 1merphos 1liposomal doxorubicin 1fludarabine phosphate 1dostarlimab 1capmatinib 1cabozantinib 1brigimadlin 1apatinib 1anlotinib 1Zoledronic Acid 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × anlotinib × Sarcoma × Clear all
NCT02449343 2017-04-25

Study of Anlotinib in Patients With Soft Tissue Sarcoma(STS)(ALTER0203)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
233 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡